PE20240634A1 - Compuestos triciclicos y usos de los mismos - Google Patents
Compuestos triciclicos y usos de los mismosInfo
- Publication number
- PE20240634A1 PE20240634A1 PE2023002241A PE2023002241A PE20240634A1 PE 20240634 A1 PE20240634 A1 PE 20240634A1 PE 2023002241 A PE2023002241 A PE 2023002241A PE 2023002241 A PE2023002241 A PE 2023002241A PE 20240634 A1 PE20240634 A1 PE 20240634A1
- Authority
- PE
- Peru
- Prior art keywords
- conh2
- halogen
- alkyl
- membered
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invencion se relaciona con compuestos triciclicos, composiciones farmaceuticas que los comprenden, metodos para prepararlos y usos de los mismos. Se trata de un compuesto de la formula (I) o una sal farmaceuticamente aceptable del mismo, o un solvato, una mezcla racemica, entre otros; en donde el anillo A es un anillo de benceno o un anillo piridina; Z es CH2, O, S o NH; R1 es de C2-6 alquinilo, -NR3R4, -SR5 y -SR6, en donde R3 es H, C1-6 alquilo, C1-6 haloalquilo, entre otros; R4 y R5 son C3-8 cicloalquilo, fenilo, heterociclilo de 4-8 miembros y heteroarilo de 5-12 miembros; R6 es -CO(C1-6 alquilo), -CO(C3-8 cicloalquilo), -CO(heterociclilo de 4-8 miembros), entre otros; R1' es halogeno, -CN, -CONH2, -OH, entre otros; R2 es -NH2, -NH(C1-6 alquilo), -N(C1-6 alquilo)2, entre otros; Cy1 es heterociclilo de 5-12 miembros o heteroarilo de 5-12 miembros, cada uno opcionalmente sustituido con uno o mas grupos independientemente elegidos de: halogeno, -CN, -CONH2, entre otros; Cy2 es fenilo o heteroarilo de 5-14 miembros, cada uno opcionalmente sustituido con uno o mas grupos independientemente elegidos de: halogeno, -CN, -CONH2, entre otros; L esta ausente, o L es S, O, NH, entre otros; y Cy2 es fenilo o heteroarilo de 5-14 miembros, cada uno esta opcionalmente sustituido con uno o mas grupos independientemente elegidos de: halogeno, -CN, -CONH2, entre otros.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110166021 | 2021-02-05 | ||
CN202210069346 | 2022-01-21 | ||
PCT/CN2022/074753 WO2022166844A1 (en) | 2021-02-05 | 2022-01-28 | Tricyclic compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240634A1 true PE20240634A1 (es) | 2024-03-26 |
Family
ID=82740848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023002241A PE20240634A1 (es) | 2021-02-05 | 2022-01-28 | Compuestos triciclicos y usos de los mismos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20240140931A1 (es) |
EP (1) | EP4288436A1 (es) |
JP (1) | JP2024506886A (es) |
KR (1) | KR20230167347A (es) |
CN (1) | CN116940573A (es) |
AU (1) | AU2022217319A1 (es) |
CA (1) | CA3206933A1 (es) |
CL (1) | CL2023002274A1 (es) |
IL (1) | IL304819A (es) |
MX (1) | MX2023009190A (es) |
PE (1) | PE20240634A1 (es) |
TW (1) | TW202241904A (es) |
WO (1) | WO2022166844A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023114954A1 (en) * | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117263942A (zh) * | 2018-03-21 | 2023-12-22 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其使用方法 |
CN117143079A (zh) * | 2018-11-06 | 2023-12-01 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
JP2022506887A (ja) * | 2018-11-07 | 2022-01-17 | シャンハイ リンジーン バイオファーマ カンパニー リミテッド | 窒素含有縮合複素環系shp2阻害剤化合物、製造方法及び使用 |
BR112021009880A2 (pt) * | 2018-11-30 | 2021-08-17 | Tuojie Biotech (Shanghai) Co., Ltd. | pirimidina e derivado de heterociclo de nitrogênio de cinco membros, método de preparação para os mesmos e usos médicos dos mesmos |
KR20220054285A (ko) * | 2019-06-28 | 2022-05-02 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | 피리미딘 5 원 질소 헤테로고리형 유도체, 이의 제조 방법 및 이의 약학적 용도 |
CN113754683A (zh) * | 2020-06-05 | 2021-12-07 | 上海奕拓医药科技有限责任公司 | 同位素取代的螺芳环化合物及其应用 |
-
2022
- 2022-01-28 US US18/264,386 patent/US20240140931A1/en active Pending
- 2022-01-28 CN CN202280012558.4A patent/CN116940573A/zh active Pending
- 2022-01-28 KR KR1020237030016A patent/KR20230167347A/ko unknown
- 2022-01-28 PE PE2023002241A patent/PE20240634A1/es unknown
- 2022-01-28 MX MX2023009190A patent/MX2023009190A/es unknown
- 2022-01-28 EP EP22749123.0A patent/EP4288436A1/en active Pending
- 2022-01-28 CA CA3206933A patent/CA3206933A1/en active Pending
- 2022-01-28 WO PCT/CN2022/074753 patent/WO2022166844A1/en active Application Filing
- 2022-01-28 TW TW111104077A patent/TW202241904A/zh unknown
- 2022-01-28 JP JP2023547520A patent/JP2024506886A/ja active Pending
- 2022-01-28 AU AU2022217319A patent/AU2022217319A1/en active Pending
-
2023
- 2023-07-30 IL IL304819A patent/IL304819A/en unknown
- 2023-08-01 CL CL2023002274A patent/CL2023002274A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2022217319A1 (en) | 2023-08-17 |
CN116940573A (zh) | 2023-10-24 |
CA3206933A1 (en) | 2022-08-11 |
KR20230167347A (ko) | 2023-12-08 |
EP4288436A1 (en) | 2023-12-13 |
WO2022166844A1 (en) | 2022-08-11 |
US20240140931A1 (en) | 2024-05-02 |
CL2023002274A1 (es) | 2024-01-26 |
MX2023009190A (es) | 2023-08-21 |
TW202241904A (zh) | 2022-11-01 |
JP2024506886A (ja) | 2024-02-15 |
IL304819A (en) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20240634A1 (es) | Compuestos triciclicos y usos de los mismos | |
AR114941A1 (es) | Derivados de sulfonilurea | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
AR064921A1 (es) | Pirazol-amidas sustituidas antagonistas de receptores alfa 7 nicotinicos de acetilcolina,composiciones farmaceuticas que las contienen y usos para el tratamiento de enfermedades neurologicas,psiquiatricas e inflamatorias. | |
PE20141110A1 (es) | Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
AR078508A1 (es) | Derivados spiro [2.4]heptano puenteados, composiciones farmaceuticas y uso de los mismos | |
AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
AR035777A1 (es) | Derivados de pirazol sustituidos, procesos para su preparacion, composiciones farmaceuticas que los contienen, y su uso en medicina | |
AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
AR030243A1 (es) | Carboxamidas heterociclicas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento antiviral y metodo in vitro para inhibir el adn polimerasa viral | |
AR074817A1 (es) | Dihidropiridona-amidas como moduladores de p2x7 | |
AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
AR067927A1 (es) | Quinolinas sustituidas, composiciones y combinaciones que las comprenden y el uso de las mismas en la preparacion de un medicamento para tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio. | |
PE20221006A1 (es) | Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae" | |
AR115906A1 (es) | Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas | |
PE20210447A1 (es) | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico | |
AR112794A1 (es) | Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso en el tratamiento de enfermedades inducidas por mutaciones idh |